ScoreWhy is Hansa Biopharma AB ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -5.08% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -118.62
- NET SALES(Q) At SEK 34.57 MM has Fallen at -37.79%
- PRE-TAX PROFIT(Q) Lowest at SEK -195.87 MM
- RAW MATERIAL COST(Y) Grown by 13.13% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 38.63%, its profits have risen by 40.8%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
105.26%
EBIT Growth (5y)
-5.08%
EBIT to Interest (avg)
-118.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0.32
Tax Ratio
0.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-37.08
EV to EBIT
-6.41
EV to EBITDA
-6.41
EV to Capital Employed
23.01
EV to Sales
15.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-358.90%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -554.28 MM
NET PROFIT(HY)
Higher at SEK -361.36 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -169.22 %
-17What is not working for the Company
NET SALES(Q)
At SEK 34.57 MM has Fallen at -37.79%
PRE-TAX PROFIT(Q)
Lowest at SEK -195.87 MM
RAW MATERIAL COST(Y)
Grown by 13.13% (YoY
INVENTORY TURNOVER RATIO(HY)
Lowest at 17.2 times
NET PROFIT(Q)
Lowest at SEK -196.32 MM
Here's what is working for Hansa Biopharma AB
Operating Cash Flow
Highest at SEK -554.28 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Debt-Equity Ratio
Lowest at -169.22 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Hansa Biopharma AB
Net Sales
At SEK 34.57 MM has Fallen at -37.79%
over average net sales of the previous four periods of SEK 55.57 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (SEK MM)
Pre-Tax Profit
At SEK -195.87 MM has Fallen at -66.94%
over average net sales of the previous four periods of SEK -117.33 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (SEK MM)
Net Profit
At SEK -196.32 MM has Fallen at -66.52%
over average net sales of the previous four periods of SEK -117.89 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (SEK MM)
Pre-Tax Profit
Lowest at SEK -195.87 MM and Fallen
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (SEK MM)
Net Profit
Lowest at SEK -196.32 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (SEK MM)
Inventory Turnover Ratio
Lowest at 17.2 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Raw Material Cost
Grown by 13.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
